source
- GSK shelves cough drug acquired in $2B dealMixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.BioPharma Dive · 14d ago↗ source
- How well are AI-discovered drugs faring in the clinic?Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.BioPharma Dive · 14d ago↗ source
- BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsAnother biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…Fierce Biotech · 14d ago↗ source